_id
690dafb2ccc777a4e85d0b22
Ticker
APGE
Name
Apogee Therapeutics, Inc. Common Stock
Exchange
NASDAQ
Address
Building 17, Waltham, MA, United States, 02453
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.apogeetherapeutics.com
Description
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications. The company develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of AD, which is in phase 2 clinical trials; and for the treatment of asthma and EoE which is in phase 1 clinical trial. It also develops APG279 that is in preclinical stage for the treatment of AD; APG990, an SQ extended half-life mAb for the treatment of AD; APG333, a human mAb against thymic stromal lymphopoietin for the treatment of asthma and COPD; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
Last Close
78.95
Volume
76403
Current Price
79.91
Change
-0.86
Last Updated
2026-01-20T15:30:46.089Z
Image
data:image/webp;base64,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
Ipo Date
2023-07-14T00:00:00.000Z
Market Cap
5518224896
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.8401
Sentiment Sources
12
Rating
5
Target Price
103.1429
Strong Buy
9
Buy
0
Hold
0
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
0
Cost Of Revenue
400000
Gross Profit
-400000
Operating Expenses
70878000
Operating Income
-71278000
Interest Expense
-
Pretax Income
-64959999
Net Income
-65021000
Eps
-1.106293558256494
Dividends Per Share
-
Shares Outstanding
54833587
Income Tax Expense
61000
EBITDA
-64559999
Operating Margin
-
Total Other Income Expense Net
6318000
Cash
107914000
Short Term Investments
419375000
Receivables
4479000
Inventories
-
Total Current Assets
540097000
Property Plant Equipment
15678000
Total Assets
626159000
Payables
376000
Short Term Debt
4079000
Long Term Debt
-
Total Liabilities
39821000
Equity
586338000
Bs_currency_symbol
USD
Depreciation
406000
Change In Working Capital
-837000
Cash From Operations
-54255000
Capital Expenditures
0
Cash From Investing
17945000
Cash From Financing
19738000
Net Change In Cash
-16572000
Cf_currency_symbol
USD
PE
-
PB
8.010070717248412
ROE
-11.089337549331614
ROA
-10.38410371806522
FCF
-54255000
Fcf Percent
-
Piotroski FScore
1
Health Score
35
Deep Value Investing Score
3
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
3.8
Garp Investing Score
2
Growth Investing Score
0.5
Momentum Investing Score
2
Net Net Investing Score
2.5
Quality Investing Score
2.5
Value Investing Score
3
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
0
Quarters > 0 > income Statement > cost Of Revenue
400000
Quarters > 0 > income Statement > gross Profit
-400000
Quarters > 0 > income Statement > operating Expenses
70878000
Quarters > 0 > income Statement > operating Income
-71278000
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
-64959999
Quarters > 0 > income Statement > net Income
-65021000
Quarters > 0 > income Statement > eps
-1.106293558256494
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
58773731
Quarters > 0 > income Statement > income Tax Expense
61000
Quarters > 0 > income Statement > EBITDA
-64559999
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
6318000
Quarters > 0 > income Statement > currency_symbol
USD
Quarters > 0 > balance Sheet > cash
107914000
Quarters > 0 > balance Sheet > short Term Investments
419375000
Quarters > 0 > balance Sheet > receivables
4479000
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
540097000
Quarters > 0 > balance Sheet > property Plant Equipment
15678000
Quarters > 0 > balance Sheet > total Assets
626159000
Quarters > 0 > balance Sheet > payables
376000
Quarters > 0 > balance Sheet > short Term Debt
4079000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
39821000
Quarters > 0 > balance Sheet > equity
586338000
Quarters > 0 > balance Sheet > currency_symbol
USD
Quarters > 0 > cash Flow > net Income
-65021000
Quarters > 0 > cash Flow > depreciation
406000
Quarters > 0 > cash Flow > change In Working Capital
-837000
Quarters > 0 > cash Flow > cash From Operations
-54255000
Quarters > 0 > cash Flow > capital Expenditures
0
Quarters > 0 > cash Flow > cash From Investing
17945000
Quarters > 0 > cash Flow > cash From Financing
19738000
Quarters > 0 > cash Flow > net Change In Cash
-16572000
Quarters > 0 > cash Flow > currency_symbol
USD
Quarters > 0 > ratios > PE
-1.106293558256494
Quarters > 0 > ratios > PB
8.010070717248412
Quarters > 0 > ratios > ROE
-11.089337549331614
Quarters > 0 > ratios > ROA
-10.38410371806522
Quarters > 0 > ratios > FCF
-54255000
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
35
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
0
Quarters > 1 > income Statement > cost Of Revenue
400000
Quarters > 1 > income Statement > gross Profit
-400000
Quarters > 1 > income Statement > operating Expenses
73165000
Quarters > 1 > income Statement > operating Income
-73165000
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
-66024000
Quarters > 1 > income Statement > net Income
-66096000
Quarters > 1 > income Statement > eps
-1.1312317870929218
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
58428344
Quarters > 1 > income Statement > income Tax Expense
72000
Quarters > 1 > income Statement > EBITDA
-72766000
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
7141000
Quarters > 1 > income Statement > currency_symbol
USD
Quarters > 1 > balance Sheet > cash
124192000
Quarters > 1 > balance Sheet > short Term Investments
381228000
Quarters > 1 > balance Sheet > receivables
4136000
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
516122000
Quarters > 1 > balance Sheet > property Plant Equipment
17024000
Quarters > 1 > balance Sheet > total Assets
657772000
Quarters > 1 > balance Sheet > payables
5678000
Quarters > 1 > balance Sheet > short Term Debt
4025000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
38371000
Quarters > 1 > balance Sheet > equity
619401000
Quarters > 1 > balance Sheet > currency_symbol
USD
Quarters > 1 > cash Flow > net Income
-66096000
Quarters > 1 > cash Flow > depreciation
399000
Quarters > 1 > cash Flow > change In Working Capital
-6837000
Quarters > 1 > cash Flow > cash From Operations
-62029000
Quarters > 1 > cash Flow > capital Expenditures
768000
Quarters > 1 > cash Flow > cash From Investing
78125000
Quarters > 1 > cash Flow > cash From Financing
1180000
Quarters > 1 > cash Flow > net Change In Cash
17276000
Quarters > 1 > cash Flow > currency_symbol
USD
Quarters > 1 > ratios > PE
-1.1312317870929218
Quarters > 1 > ratios > PB
7.537942252337339
Quarters > 1 > ratios > ROE
-10.670954680408975
Quarters > 1 > ratios > ROA
-10.04846664193672
Quarters > 1 > ratios > FCF
-62797000
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
35
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
0
Quarters > 2 > income Statement > cost Of Revenue
207000
Quarters > 2 > income Statement > gross Profit
-207000
Quarters > 2 > income Statement > operating Expenses
63096000
Quarters > 2 > income Statement > operating Income
-63096000
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
-55256000
Quarters > 2 > income Statement > net Income
-55339000
Quarters > 2 > income Statement > eps
-0.9509191743274265
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
58195272
Quarters > 2 > income Statement > income Tax Expense
83000
Quarters > 2 > income Statement > EBITDA
-62889000
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
7840000
Quarters > 2 > income Statement > currency_symbol
USD
Quarters > 2 > balance Sheet > cash
106916000
Quarters > 2 > balance Sheet > short Term Investments
406413000
Quarters > 2 > balance Sheet > receivables
5011000
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
521531000
Quarters > 2 > balance Sheet > property Plant Equipment
17186000
Quarters > 2 > balance Sheet > total Assets
714162000
Quarters > 2 > balance Sheet > payables
2445000
Quarters > 2 > balance Sheet > short Term Debt
3976000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
40800000
Quarters > 2 > balance Sheet > equity
673362000
Quarters > 2 > balance Sheet > currency_symbol
USD
Quarters > 2 > cash Flow > net Income
-55339000
Quarters > 2 > cash Flow > depreciation
207000
Quarters > 2 > cash Flow > change In Working Capital
-2949000
Quarters > 2 > cash Flow > cash From Operations
-48477000
Quarters > 2 > cash Flow > capital Expenditures
4317000
Quarters > 2 > cash Flow > cash From Investing
12982000
Quarters > 2 > cash Flow > cash From Financing
622000
Quarters > 2 > cash Flow > net Change In Cash
-34873000
Quarters > 2 > cash Flow > currency_symbol
USD
Quarters > 2 > ratios > PE
-0.9509191743274265
Quarters > 2 > ratios > PB
6.9062171395475245
Quarters > 2 > ratios > ROE
-8.218313477743026
Quarters > 2 > ratios > ROA
-7.748802092522425
Quarters > 2 > ratios > FCF
-52794000
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
35
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
130000
Quarters > 3 > income Statement > cost Of Revenue
-
Quarters > 3 > income Statement > gross Profit
65000
Quarters > 3 > income Statement > operating Expenses
75881000
Quarters > 3 > income Statement > operating Income
-75881000
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-67200000
Quarters > 3 > income Statement > net Income
-67218000
Quarters > 3 > income Statement > eps
-1.2178504061612092
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
55193971
Quarters > 3 > income Statement > income Tax Expense
18000
Quarters > 3 > income Statement > EBITDA
-75805000
Quarters > 3 > income Statement > operating Margin
-58370.00000000001
Quarters > 3 > income Statement > total Other Income Expense Net
8681000
Quarters > 3 > income Statement > currency_symbol
USD
Quarters > 3 > balance Sheet > cash
141789000
Quarters > 3 > balance Sheet > short Term Investments
378864000
Quarters > 3 > balance Sheet > receivables
4697000
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
529713000
Quarters > 3 > balance Sheet > property Plant Equipment
13324000
Quarters > 3 > balance Sheet > total Assets
753951000
Quarters > 3 > balance Sheet > payables
1071000
Quarters > 3 > balance Sheet > short Term Debt
3234000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
37157000
Quarters > 3 > balance Sheet > equity
716794000
Quarters > 3 > balance Sheet > currency_symbol
USD
Quarters > 3 > cash Flow > net Income
-67218000
Quarters > 3 > cash Flow > depreciation
76000
Quarters > 3 > cash Flow > change In Working Capital
-5956000
Quarters > 3 > cash Flow > cash From Operations
-67714000
Quarters > 3 > cash Flow > capital Expenditures
1000
Quarters > 3 > cash Flow > cash From Investing
46367000
Quarters > 3 > cash Flow > cash From Financing
44356000
Quarters > 3 > cash Flow > net Change In Cash
23009000
Quarters > 3 > cash Flow > currency_symbol
USD
Quarters > 3 > ratios > PE
-1.2178504061612092
Quarters > 3 > ratios > PB
6.153162864937485
Quarters > 3 > ratios > ROE
-9.377589656163417
Quarters > 3 > ratios > ROA
-8.915433496341274
Quarters > 3 > ratios > FCF
-67715000
Quarters > 3 > ratios > Piotroski FScore
0
Quarters > 3 > ratios > fcf Percent
-520.8846153846154
Quarters > 3 > health Score
26
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
0
Annuals > 0 > income Statement > cost Of Revenue
189000
Annuals > 0 > income Statement > gross Profit
-189000
Annuals > 0 > income Statement > operating Expenses
216870000
Annuals > 0 > income Statement > operating Income
-216870000
Annuals > 0 > income Statement > interest Expense
-
Annuals > 0 > income Statement > pretax Income
-182128000
Annuals > 0 > income Statement > net Income
-182146000
Annuals > 0 > income Statement > eps
-3.3001068178261717
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
55193971
Annuals > 0 > income Statement > income Tax Expense
18000
Annuals > 0 > income Statement > EBITDA
-216681000
Annuals > 0 > income Statement > operating Margin
-
Annuals > 0 > income Statement > total Other Income Expense Net
34742000
Annuals > 0 > income Statement > currency_symbol
USD
Annuals > 0 > balance Sheet > cash
141789000
Annuals > 0 > balance Sheet > short Term Investments
378864000
Annuals > 0 > balance Sheet > receivables
4697000
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
529713000
Annuals > 0 > balance Sheet > property Plant Equipment
13324000
Annuals > 0 > balance Sheet > total Assets
753951000
Annuals > 0 > balance Sheet > payables
1071000
Annuals > 0 > balance Sheet > short Term Debt
3234000
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
37157000
Annuals > 0 > balance Sheet > equity
716794000
Annuals > 0 > balance Sheet > currency_symbol
USD
Annuals > 0 > cash Flow > net Income
-182146000
Annuals > 0 > cash Flow > depreciation
189000
Annuals > 0 > cash Flow > change In Working Capital
-2002000
Annuals > 0 > cash Flow > cash From Operations
-171174000
Annuals > 0 > cash Flow > capital Expenditures
1152000
Annuals > 0 > cash Flow > cash From Investing
-300462000
Annuals > 0 > cash Flow > cash From Financing
495109000
Annuals > 0 > cash Flow > net Change In Cash
23473000
Annuals > 0 > cash Flow > currency_symbol
USD
Annuals > 0 > ratios > PE
-3.3001068178261717
Annuals > 0 > ratios > PB
6.153162864937485
Annuals > 0 > ratios > ROE
-25.41120600897887
Annuals > 0 > ratios > ROA
-24.15886443548719
Annuals > 0 > ratios > FCF
-172326000
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-
Annuals > 0 > health Score
26
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
0
Annuals > 1 > income Statement > cost Of Revenue
-
Annuals > 1 > income Statement > gross Profit
-
Annuals > 1 > income Statement > operating Expenses
93003000
Annuals > 1 > income Statement > operating Income
-93003000
Annuals > 1 > income Statement > interest Expense
0
Annuals > 1 > income Statement > pretax Income
-83985000
Annuals > 1 > income Statement > net Income
-83985000
Annuals > 1 > income Statement > eps
-1.6579584939265735
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
50655671
Annuals > 1 > income Statement > income Tax Expense
-93003
Annuals > 1 > income Statement > EBITDA
-74967000
Annuals > 1 > income Statement > operating Margin
-
Annuals > 1 > income Statement > total Other Income Expense Net
9018000
Annuals > 1 > income Statement > currency_symbol
USD
Annuals > 1 > balance Sheet > cash
118316000
Annuals > 1 > balance Sheet > short Term Investments
277143000
Annuals > 1 > balance Sheet > receivables
1214000
Annuals > 1 > balance Sheet > inventories
-
Annuals > 1 > balance Sheet > total Current Assets
398409000
Annuals > 1 > balance Sheet > property Plant Equipment
2594000
Annuals > 1 > balance Sheet > total Assets
401404000
Annuals > 1 > balance Sheet > payables
2143000
Annuals > 1 > balance Sheet > short Term Debt
1101000
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
21491000
Annuals > 1 > balance Sheet > equity
379913000
Annuals > 1 > balance Sheet > currency_symbol
USD
Annuals > 1 > cash Flow > net Income
-83985000
Annuals > 1 > cash Flow > depreciation
0
Annuals > 1 > cash Flow > change In Working Capital
6105000
Annuals > 1 > cash Flow > cash From Operations
-74761000
Annuals > 1 > cash Flow > capital Expenditures
167000
Annuals > 1 > cash Flow > cash From Investing
-273910000
Annuals > 1 > cash Flow > cash From Financing
315391000
Annuals > 1 > cash Flow > net Change In Cash
-33280000
Annuals > 1 > cash Flow > currency_symbol
USD
Annuals > 1 > ratios > PE
-1.6579584939265735
Annuals > 1 > ratios > PB
10.654793780707688
Annuals > 1 > ratios > ROE
-22.10637698631002
Annuals > 1 > ratios > ROA
-20.922810933622983
Annuals > 1 > ratios > FCF
-74928000
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-
Annuals > 1 > health Score
26
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
0
Annuals > 2 > income Statement > cost Of Revenue
-
Annuals > 2 > income Statement > gross Profit
-
Annuals > 2 > income Statement > operating Expenses
30727000
Annuals > 2 > income Statement > operating Income
-30727000
Annuals > 2 > income Statement > interest Expense
9150000
Annuals > 2 > income Statement > pretax Income
-39785000
Annuals > 2 > income Statement > net Income
-39785000
Annuals > 2 > income Statement > eps
-0.7851120418130723
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
50674296
Annuals > 2 > income Statement > income Tax Expense
-33520
Annuals > 2 > income Statement > EBITDA
-39785000
Annuals > 2 > income Statement > operating Margin
-
Annuals > 2 > income Statement > total Other Income Expense Net
-9058000
Annuals > 2 > income Statement > currency_symbol
USD
Annuals > 2 > balance Sheet > cash
151890000
Annuals > 2 > balance Sheet > short Term Investments
0
Annuals > 2 > balance Sheet > receivables
-
Annuals > 2 > balance Sheet > inventories
-
Annuals > 2 > balance Sheet > total Current Assets
152055000
Annuals > 2 > balance Sheet > property Plant Equipment
0
Annuals > 2 > balance Sheet > total Assets
152055000
Annuals > 2 > balance Sheet > payables
418000
Annuals > 2 > balance Sheet > short Term Debt
-
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
9980000
Annuals > 2 > balance Sheet > equity
142075000
Annuals > 2 > balance Sheet > currency_symbol
USD
Annuals > 2 > cash Flow > net Income
-39785000
Annuals > 2 > cash Flow > depreciation
33520361
Annuals > 2 > cash Flow > change In Working Capital
9815000
Annuals > 2 > cash Flow > cash From Operations
-16427000
Annuals > 2 > cash Flow > capital Expenditures
0
Annuals > 2 > cash Flow > cash From Investing
-
Annuals > 2 > cash Flow > cash From Financing
168317000
Annuals > 2 > cash Flow > net Change In Cash
151890000
Annuals > 2 > cash Flow > currency_symbol
USD
Annuals > 2 > ratios > PE
-0.7851120418130723
Annuals > 2 > ratios > PB
28.501727913848317
Annuals > 2 > ratios > ROE
-28.002815414393805
Annuals > 2 > ratios > ROA
-26.16487455197133
Annuals > 2 > ratios > FCF
-16427000
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-
Annuals > 2 > health Score
26
Valuation > metrics > PE
-1.106293558256494
Valuation > metrics > PB
8.010070717248412
Valuation > final Score
20
Valuation > verdict
167.0% Overvalued
Profitability > metrics > ROE
-11.089337549331614
Profitability > metrics > ROA
-12.038763407313871
Profitability > final Score
15
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.06791475224188097
Risk > metrics > Interest Coverage
-178.195
Risk > final Score
-653
Risk > verdict
High
Liquidity > metrics > Current Ratio
121.23389450056116
Liquidity > metrics > Quick Ratio
121.23389450056116
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
20
Prev Valuations > 1
20
Prev Valuations > 2
20
Prev Profitabilities > 0
15
Prev Profitabilities > 1
15
Prev Profitabilities > 2
0
Prev Risks > 0
17
Prev Risks > 1
27
Prev Risks > 2
25
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T21:23:59.156Z
Earnings History > 0 > period
2025-12-31
Earnings History > 0 > report Date
2026-03-10
Earnings History > 0 > date
2025-12-31
Earnings History > 0 > before After Market
-
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
0
Earnings History > 0 > eps Estimate
-0.62
Earnings History > 0 > eps Difference
0.62
Earnings History > 0 > surprise Percent
100
Earnings History > 1 > period
2025-09-30
Earnings History > 1 > report Date
2025-11-10
Earnings History > 1 > date
2025-09-30
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
-1.11
Earnings History > 1 > eps Estimate
-0.61
Earnings History > 1 > eps Difference
-0.5
Earnings History > 1 > surprise Percent
-81.9672
Earnings History > 2 > period
2025-06-30
Earnings History > 2 > report Date
2025-08-11
Earnings History > 2 > date
2025-06-30
Earnings History > 2 > before After Market
-
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
-1.13
Earnings History > 2 > eps Estimate
-0.62
Earnings History > 2 > eps Difference
-0.51
Earnings History > 2 > surprise Percent
-82.2581
Earnings History > 3 > period
2025-03-31
Earnings History > 3 > report Date
2025-05-12
Earnings History > 3 > date
2025-03-31
Earnings History > 3 > before After Market
-
Earnings History > 3 > currency
-
Earnings History > 3 > eps Actual
-0.95
Earnings History > 3 > eps Estimate
-0.58
Earnings History > 3 > eps Difference
-0.37
Earnings History > 3 > surprise Percent
-63.7931
Earnings History > 4 > period
2024-12-31
Earnings History > 4 > report Date
2025-03-03
Earnings History > 4 > date
2024-12-31
Earnings History > 4 > before After Market
-
Earnings History > 4 > currency
-
Earnings History > 4 > eps Actual
-1.18
Earnings History > 4 > eps Estimate
-0.62
Earnings History > 4 > eps Difference
-0.56
Earnings History > 4 > surprise Percent
-90.3226
Earnings History > 5 > period
2024-09-30
Earnings History > 5 > report Date
2024-11-13
Earnings History > 5 > date
2024-09-30
Earnings History > 5 > before After Market
-
Earnings History > 5 > currency
USD
Earnings History > 5 > eps Actual
-0.8631
Earnings History > 5 > eps Estimate
-0.56
Earnings History > 5 > eps Difference
-0.3031
Earnings History > 5 > surprise Percent
-54.125
Earnings History > 6 > period
2024-06-30
Earnings History > 6 > report Date
2024-08-12
Earnings History > 6 > date
2024-06-30
Earnings History > 6 > before After Market
-
Earnings History > 6 > currency
USD
Earnings History > 6 > eps Actual
-0.6
Earnings History > 6 > eps Estimate
-0.52
Earnings History > 6 > eps Difference
-0.08
Earnings History > 6 > surprise Percent
-15.3846
Earnings History > 7 > period
2024-03-31
Earnings History > 7 > report Date
2024-05-13
Earnings History > 7 > date
2024-03-31
Earnings History > 7 > before After Market
BeforeMarket
Earnings History > 7 > currency
USD
Earnings History > 7 > eps Actual
-0.64
Earnings History > 7 > eps Estimate
-0.61
Earnings History > 7 > eps Difference
-0.03
Earnings History > 7 > surprise Percent
-4.918
Earnings History > 8 > period
2023-12-31
Earnings History > 8 > report Date
2024-03-05
Earnings History > 8 > date
2023-12-31
Earnings History > 8 > before After Market
BeforeMarket
Earnings History > 8 > currency
USD
Earnings History > 8 > eps Actual
-0.32
Earnings History > 8 > eps Estimate
-0.49
Earnings History > 8 > eps Difference
0.17
Earnings History > 8 > surprise Percent
34.6939
Earnings History > 9 > period
2023-09-30
Earnings History > 9 > report Date
2023-11-13
Earnings History > 9 > date
2023-09-30
Earnings History > 9 > before After Market
BeforeMarket
Earnings History > 9 > currency
USD
Earnings History > 9 > eps Actual
-0.51
Earnings History > 9 > eps Estimate
-0.41
Earnings History > 9 > eps Difference
-0.1
Earnings History > 9 > surprise Percent
-24.3902
Earnings History > 10 > period
2023-06-30
Earnings History > 10 > report Date
2023-08-28
Earnings History > 10 > date
2023-06-30
Earnings History > 10 > before After Market
BeforeMarket
Earnings History > 10 > currency
USD
Earnings History > 10 > eps Actual
-3.78
Earnings History > 10 > eps Estimate
-1.7
Earnings History > 10 > eps Difference
-2.08
Earnings History > 10 > surprise Percent
-122.3529
Earnings History > 11 > period
2023-03-31
Earnings History > 11 > report Date
2023-05-31
Earnings History > 11 > date
2023-03-31
Earnings History > 11 > before After Market
-
Earnings History > 11 > currency
USD
Earnings History > 11 > eps Actual
-2.38
Earnings History > 11 > eps Estimate
0
Earnings History > 11 > eps Difference
-2.38
Earnings History > 11 > surprise Percent
-
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications. The company develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of AD, which is in phase 2 clinical trials; and for the treatment of asthma and EoE which is in phase 1 clinical trial. It also develops APG279 that is in preclinical stage for the treatment of AD; APG990, an SQ extended half-life mAb for the treatment of AD; APG333, a human mAb against thymic stromal lymphopoietin for the treatment of asthma and COPD; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AApogee Therapeutics: 2026 Inflection Point In Immunology (NASDAQ:APGE) Seeking Alpha
Read more →A Look At Apogee Therapeutics (APGE) Valuation After Positive Asthma Trial Data And 2026 Pipeline Milestones simplywall.st
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
STRONG BUY
Target Price:
$103.1429
Analyst Picks
Strong Buy
9
Buy
0
Hold
0
Sell
0
Strong Sell
0
Sentiment:
Bullish
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Apogee Therapeutics, Inc. Common Stock
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2025-12-31
EPS Estimate
-0.62
Date
2025-09-30
EPS Actual
-1.11
EPS Estimate
-0.61
EPS Difference
-0.5
Surprise Percent
-81.9672%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.